Children's Hospital Boston last week unveiled a technology-development fund designed to help move early-stage biomedical technologies from the research hospital to the market, according to the hospital.

The fund will dole out proof-of-concept grants worth as much as $50,000 and technology-development grants worth between $150,000 and $200,000 to research projects at Children's. Awardees will be chosen by an external advisory board comprising members of the pharmaceutical, biotech, medical device, and investment communities, the hospital said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.